# EDGAR Filing Document

**Accession Number:** 0000826644
**File Stem:** 0000826644-26-000103
**Filing Date:** 2026-4
**Character Count:** 49017
**Document Hash:** aadae90702b17eee19a8ef00b830f8bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000826644-26-000103.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0000826644-26-000103

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260131

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260401

**PERIOD START**: 20261031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS)
- **CENTRAL INDEX KEY:** 0000826644

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-05426
- **FILM NUMBER:** 26825664

**BUSINESS ADDRESS:**
- **STREET 1:** 11 GREENWAY PLAZA
- **STREET 2:** SUITE 1000
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77046
- **BUSINESS PHONE:** 7136261919

**MAIL ADDRESS:**
- **STREET 1:** 11 GREENWAY PLAZA
- **STREET 2:** SUITE 1000
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77046

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIM INVESTMENT FUNDS
- **DATE OF NAME CHANGE:** 19980529

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** G T INVESTMENT FUNDS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** G T GLOBAL INCOME SERIES INC
- **DATE OF NAME CHANGE:** 19890521

## Series and Classes Contracts Data

### INVESCO Health Care Fund (Series ID: S000000235)

| Class ID   | Class Name     | Ticker Symbol   |
|:---|:---|:---|
| C000000565 | Class A        | GGHCX           |
| C000000567 | Class C        | GTHCX           |
| C000029647 | Investor Class | GTHIX           |
| C000071224 | Class Y        | GGHYX           |
| C000188882 | Class R6       |  |
| C000265799 | Class R        | GTHRX           |

## Nport-Ex

**Schedule of Investments**<sup>(a)</sup> 

*January 31, 2026*

*(Unaudited)*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| **Shares** | **Shares** | **Value** |
| **Common Stocks & Other Equity Interests–96.78%** | **Common Stocks & Other Equity Interests–96.78%** | **Common Stocks & Other Equity Interests–96.78%** |
| **Biotechnology–28.59%** | **Biotechnology–28.59%** | **Biotechnology–28.59%** |
| AbbVie, Inc. | 277017 | &nbsp;&nbsp; $61777561 |
| ADMA Biologics, Inc.<sup>(b)</sup>  | 136705 | &nbsp;&nbsp; 2364996 |
| Alnylam Pharmaceuticals, Inc.<sup>(b)</sup>  | 36773 | &nbsp;&nbsp; 12431480 |
| argenx SE, ADR (Netherlands)<sup>(b)</sup>  | 52976 | &nbsp;&nbsp; 44526328 |
| Arrowhead Pharmaceuticals, Inc.<sup>(b)</sup>  | 18515 | &nbsp;&nbsp; 1283645 |
| Ascendis Pharma A/S, ADR (Denmark)<sup>(b)</sup>  | 94558 | &nbsp;&nbsp; 21379564 |
| BeOne Medicines Ltd., ADR<sup>(b)</sup>  | 9251 | &nbsp;&nbsp; 3148855 |
| BridgeBio Pharma, Inc.<sup>(b)</sup>  | 216227 | &nbsp;&nbsp; 16707860 |
| Caris Life Sciences, Inc.<sup>(b)</sup>  | 110484 | &nbsp;&nbsp; 2558809 |
| Cogent Biosciences, Inc.<sup>(b)(c)</sup>  | 74261 | &nbsp;&nbsp; 2666713 |
| Cytokinetics, Inc.<sup>(b)(c)</sup>  | 48114 | &nbsp;&nbsp; 3040324 |
| Exelixis, Inc.<sup>(b)</sup>  | 96756 | &nbsp;&nbsp; 4001828 |
| Gilead Sciences, Inc. | 337004 | &nbsp;&nbsp; 47837718 |
| Halozyme Therapeutics, Inc.<sup>(b)</sup>  | 155098 | &nbsp;&nbsp; 11122078 |
| Insmed, Inc.<sup>(b)</sup>  | 120502 | &nbsp;&nbsp; 18903149 |
| Ionis Pharmaceuticals, Inc.<sup>(b)(c)</sup>  | 107312 | &nbsp;&nbsp; 8871483 |
| Madrigal Pharmaceuticals, Inc.<sup>(b)(c)</sup>  | 21162 | &nbsp;&nbsp; 10354778 |
| Natera, Inc.<sup>(b)</sup>  | 86013 | &nbsp;&nbsp; 19881045 |
| Nuvalent, Inc., Class A<sup>(b)(c)</sup>  | 33246 | &nbsp;&nbsp; 3420681 |
| Protagonist Therapeutics, Inc.<sup>(b)</sup>  | 103952 | &nbsp;&nbsp; 8503274 |
| Regeneron Pharmaceuticals, Inc. | 18122 | &nbsp;&nbsp; 13436557 |
| Revolution Medicines, Inc.<sup>(b)</sup>  | 27141 | &nbsp;&nbsp; 2631320 |
| Rhythm Pharmaceuticals, Inc.<sup>(b)</sup>  | 30683 | &nbsp;&nbsp; 3145621 |
| United Therapeutics Corp.<sup>(b)</sup>  | 26773 | &nbsp;&nbsp; 12569656 |
| Vertex Pharmaceuticals, Inc.<sup>(b)</sup>  | 32280 | &nbsp;&nbsp; 15168372 |
|  |  | &nbsp;&nbsp; 351733695 |
| **Health Care Distributors–8.73%** | **Health Care Distributors–8.73%** | **Health Care Distributors–8.73%** |
| Cardinal Health, Inc. | 44523 | &nbsp;&nbsp; 9567102 |
| Cencora, Inc. | 162214 | &nbsp;&nbsp; 58270513 |
| McKesson Corp. | 47553 | &nbsp;&nbsp; 39526529 |
|  |  | &nbsp;&nbsp; 107364144 |
| **Health Care Equipment–13.83%** | **Health Care Equipment–13.83%** | **Health Care Equipment–13.83%** |
| Boston Scientific Corp.<sup>(b)</sup>  | 670569 | &nbsp;&nbsp; 62718318 |
| Edwards Lifesciences Corp.<sup>(b)</sup>  | 140197 | &nbsp;&nbsp; 11406428 |
| Globus Medical, Inc., Class A<sup>(b)</sup>  | 65282 | &nbsp;&nbsp; 5919772 |
| IDEXX Laboratories, Inc.<sup>(b)</sup>  | 29150 | &nbsp;&nbsp; 19543909 |
| Insulet Corp.<sup>(b)</sup>  | 52804 | &nbsp;&nbsp; 13507791 |
| Intuitive Surgical, Inc.<sup>(b)</sup>  | 45537 | &nbsp;&nbsp; 22960666 |
| IRhythm Holdings, Inc.<sup>(b)</sup>  | 47015 | &nbsp;&nbsp; 7264288 |
| LeMaitre Vascular, Inc.<sup>(c)</sup>  | 44039 | &nbsp;&nbsp; 3741994 |
| STERIS PLC | 29417 | &nbsp;&nbsp; 7724904 |
| Stryker Corp. | 29378 | &nbsp;&nbsp; 10856934 |
| TransMedics Group, Inc.<sup>(b)(c)</sup>  | 33601 | &nbsp;&nbsp; 4501694 |
|  |  | &nbsp;&nbsp; 170146698 |
| **Health Care Facilities–4.30%** | **Health Care Facilities–4.30%** | **Health Care Facilities–4.30%** |
| Encompass Health Corp. | 143359 | &nbsp;&nbsp; 13551726 |
| HCA Healthcare, Inc. | 49432 | &nbsp;&nbsp; 24136163 |
| Tenet Healthcare Corp.<sup>(b)</sup>  | 80222 | &nbsp;&nbsp; 15184420 |
|  |  | &nbsp;&nbsp; 52872309 |
| **Health Care REITs–1.84%** | **Health Care REITs–1.84%** | **Health Care REITs–1.84%** |
| Welltower, Inc. | 120441 | &nbsp;&nbsp; 22686267 |

---

---

| | | |
|:---|:---|:---|
| **Shares** | **Shares** | **Value** |
| **Health Care Services–5.68%** | **Health Care Services–5.68%** | **Health Care Services–5.68%** |
| BillionToOne, Inc.<sup>(b)(c)</sup>  | 14768 | &nbsp;&nbsp; $1218508 |
| BrightSpring Health Services, Inc.<sup>(b)(c)</sup>  | 482157 | &nbsp;&nbsp; 18934305 |
| CVS Health Corp. | 119228 | &nbsp;&nbsp; 8884871 |
| GeneDx Holdings Corp.<sup>(b)(c)</sup>  | 50738 | &nbsp;&nbsp; 4884040 |
| Guardant Health, Inc.<sup>(b)</sup>  | 189772 | &nbsp;&nbsp; 21641599 |
| Labcorp Holdings, Inc. | 22180 | &nbsp;&nbsp; 6022314 |
| Quest Diagnostics, Inc. | 20984 | &nbsp;&nbsp; 3924637 |
| RadNet, Inc.<sup>(b)</sup>  | 62732 | &nbsp;&nbsp; 4397513 |
|  |  | &nbsp;&nbsp; 69907787 |
| **Health Care Technology–0.30%** | **Health Care Technology–0.30%** | **Health Care Technology–0.30%** |
| Heartflow, Inc.<sup>(b)(c)</sup>  | 121178 | &nbsp;&nbsp; 3619587 |
| **Life Sciences Tools & Services–7.04%** | **Life Sciences Tools & Services–7.04%** | **Life Sciences Tools & Services–7.04%** |
| Agilent Technologies, Inc. | 87517 | &nbsp;&nbsp; 11714150 |
| BioLife Solutions, Inc.<sup>(b)</sup>  | 151657 | &nbsp;&nbsp; 3306123 |
| ICON PLC<sup>(b)</sup>  | 25368 | &nbsp;&nbsp; 4572582 |
| Lonza Group AG (Switzerland) | 14888 | &nbsp;&nbsp; 10115652 |
| Medpace Holdings, Inc.<sup>(b)</sup>  | 12424 | &nbsp;&nbsp; 7236731 |
| Mettler-Toledo International, Inc.<sup>(b)</sup>  | 9732 | &nbsp;&nbsp; 13364372 |
| Repligen Corp.<sup>(b)</sup>  | 50803 | &nbsp;&nbsp; 7588444 |
| Thermo Fisher Scientific, Inc. | 49606 | &nbsp;&nbsp; 28702528 |
|  |  | &nbsp;&nbsp; 86600582 |
| **Managed Health Care–2.25%** | **Managed Health Care–2.25%** | **Managed Health Care–2.25%** |
| Alignment Healthcare, Inc.<sup>(b)</sup>  | 309133 | &nbsp;&nbsp; 6964767 |
| HealthEquity, Inc.<sup>(b)</sup>  | 43670 | &nbsp;&nbsp; 3741209 |
| UnitedHealth Group, Inc. | 59237 | &nbsp;&nbsp; 16996872 |
|  |  | &nbsp;&nbsp; 27702848 |
| **Pharmaceuticals–24.22%** | **Pharmaceuticals–24.22%** | **Pharmaceuticals–24.22%** |
| AstraZeneca PLC, ADR (United Kingdom) | 504742 | &nbsp;&nbsp; 46824915 |
| Axsome Therapeutics, Inc.<sup>(b)</sup>  | 87700 | &nbsp;&nbsp; 16158725 |
| Eli Lilly and Co. | 113267 | &nbsp;&nbsp; 117474869 |
| Galderma Group AG, Class A (Switzerland) | 49726 | &nbsp;&nbsp; 9268874 |
| Johnson & Johnson | 184830 | &nbsp;&nbsp; 42002618 |
| Ligand Pharmaceuticals, Inc.<sup>(b)(c)</sup>  | 40048 | &nbsp;&nbsp; 7693221 |
| Phathom Pharmaceuticals, Inc.<sup>(b)(c)</sup>  | 184910 | &nbsp;&nbsp; 2527720 |
| Rapport Therapeutics, Inc.<sup>(b)(c)</sup>  | 109966 | &nbsp;&nbsp; 2926195 |
| Royalty Pharma PLC, Class A | 440990 | &nbsp;&nbsp; 18380463 |
| Sandoz Group AG (Switzerland) | 150537 | &nbsp;&nbsp; 11926418 |
| Tarsus Pharmaceuticals, Inc.<sup>(b)</sup>  | 77845 | &nbsp;&nbsp; 5024116 |
| UCB S.A. (Belgium) | 58259 | &nbsp;&nbsp; 17753000 |
|  |  | &nbsp;&nbsp; 297961134 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Common Stocks & Other Equity Interests <br> (Cost $737,952,842) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Common Stocks & Other Equity Interests <br> (Cost $737,952,842) | &nbsp;&nbsp; 1190595051 |
| **Money Market Funds–2.81%** | **Money Market Funds–2.81%** | **Money Market Funds–2.81%** |
| &nbsp;&nbsp;&nbsp; Invesco Government & Agency Portfolio, <br> Institutional Class, 3.61%<sup>(d)(e)</sup>  | 11868146 | &nbsp;&nbsp; 11868146 |

---

See accompanying notes which are an integral part of this schedule.

**Invesco Health Care Fund**

------

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares** | **Shares** | **Value** |
| **Money Market Funds–(continued)** | **Money Market Funds–(continued)** | **Money Market Funds–(continued)** | **Money Market Funds–(continued)** |
| &nbsp;&nbsp;&nbsp; Invesco Treasury Portfolio, Institutional <br> Class, 3.57%<sup>(d)(e)</sup>  | &nbsp;&nbsp;&nbsp; Invesco Treasury Portfolio, Institutional <br> Class, 3.57%<sup>(d)(e)</sup>  | 22695004 | &nbsp;&nbsp; $22695004 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Money Market Funds (Cost $34,563,150) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Money Market Funds (Cost $34,563,150) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Money Market Funds (Cost $34,563,150) | &nbsp;&nbsp; 34563150 |
| &nbsp;&nbsp;&nbsp; TOTAL INVESTMENTS IN SECURITIES <br> (excluding investments purchased <br> with cash collateral from securities <br> on loan)-99.59% <br> (Cost $772,515,992)<br>|  |  | &nbsp;&nbsp; 1225158201 |
| **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** | **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** | **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** | **Investments Purchased with Cash Collateral from** <br> **Securities on Loan** |
| **Money Market Funds–3.47%** | **Money Market Funds–3.47%** | **Money Market Funds–3.47%** | **Money Market Funds–3.47%** |
| &nbsp;&nbsp;&nbsp; Invesco Private Government Fund, <br> 3.65%<sup>(d)(e)(f)</sup>  | &nbsp;&nbsp;&nbsp; Invesco Private Government Fund, <br> 3.65%<sup>(d)(e)(f)</sup>  | 11873857 | &nbsp;&nbsp; 11873857 |

---

---

| | | |
|:---|:---|:---|
| **Shares** | **Shares** | **Value** |
| **Money Market Funds–(continued)** | **Money Market Funds–(continued)** | **Money Market Funds–(continued)** |
| Invesco Private Prime Fund, 3.80%<sup>(d)(e)(f)</sup>  | 30847581 | &nbsp;&nbsp; $30856835 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Investments Purchased with Cash Collateral <br> from Securities on Loan (Cost $42,730,692) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Investments Purchased with Cash Collateral <br> from Securities on Loan (Cost $42,730,692) | &nbsp;&nbsp; 42730692 |
| &nbsp;&nbsp;&nbsp; TOTAL INVESTMENTS IN SECURITIES–103.06% <br> (Cost $815,246,684) | &nbsp;&nbsp;&nbsp; TOTAL INVESTMENTS IN SECURITIES–103.06% <br> (Cost $815,246,684) | &nbsp;&nbsp; 1267888893 |
| OTHER ASSETS LESS LIABILITIES—(3.06)% | OTHER ASSETS LESS LIABILITIES—(3.06)% | &nbsp;&nbsp; (37660470)<br>|
| NET ASSETS–100.00% | NET ASSETS–100.00% | &nbsp;&nbsp; $1230228423 |

---

Investment Abbreviations:

ADR – American Depositary Receipt <br> REIT – Real Estate Investment Trust

Notes to Schedule of Investments:

<sup>(a)</sup> Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's. 

<sup>(b)</sup> Non-income producing security.

<sup>(c)</sup> All or a portion of this security was out on loan at January 31, 2026.

<sup>(d)</sup> Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the three months ended January 31, 2026. 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Value** <br>**October 31, 2025**<br>| **Purchases** <br>**at Cost**<br>| **Proceeds** <br>**from Sales**<br>| **Change in** <br>**Unrealized** <br>**Appreciation**<br>| **Realized** <br>**Gain** <br>**(Loss)**<br>| **Value** <br>**January 31, 2026**<br>| **Dividend Income** |
| **Investments in Affiliated Money Market Funds:** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Invesco Government & Agency Portfolio, <br> Institutional Class<br>| $9293643 | &nbsp;&nbsp; $37540135 | &nbsp;&nbsp; $(34965632) | &nbsp;&nbsp; $- | &nbsp;&nbsp; $- | &nbsp;&nbsp; $11868146 | &nbsp;&nbsp; $83432 |
| Invesco Treasury Portfolio, Institutional Class | &nbsp;&nbsp; 17913782 | &nbsp;&nbsp;&nbsp; 69717395 | &nbsp;&nbsp;&nbsp; (64936173) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp; 22695004 | &nbsp;&nbsp;&nbsp; 159306 |
| **Investments Purchased with Cash Collateral** <br> **from Securities on Loan:**<br>|  |  |  |  |  |  |  |
| Invesco Private Government Fund | &nbsp;&nbsp;&nbsp; 9367806 | &nbsp;&nbsp;&nbsp; 59473911 | &nbsp;&nbsp;&nbsp; (56967860) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp; 11873857 | &nbsp;&nbsp;&nbsp; 81,407\* |
| Invesco Private Prime Fund | &nbsp;&nbsp; 24364368 | &nbsp;&nbsp;&nbsp; 86941625 | &nbsp;&nbsp;&nbsp; (80449158) | &nbsp;&nbsp; 190 | &nbsp;&nbsp; (190) | &nbsp;&nbsp; 30856835 | &nbsp;&nbsp; 210,951\* |
| Total | $60939599 | &nbsp;&nbsp; $253673066 | &nbsp;&nbsp; $(237318823) | &nbsp;&nbsp; $190 | &nbsp;&nbsp; $(190) | &nbsp;&nbsp; $77293842 | &nbsp;&nbsp; $535096 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

\* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(e)</sup> The rate shown is the 7-day SEC standardized yield as of January 31, 2026. <br> <sup>(f)</sup> The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned.

The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.

See accompanying notes which are an integral part of this schedule.

**Invesco Health Care Fund**

------

**Notes to Quarterly Schedule of Portfolio Holdings**

*January 31, 2026*

*(Unaudited)*

**NOTE 1—Additional Valuation Information**

Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment's assigned level:

Level 1 – Prices are determined using quoted prices in an active market for identical assets.

Level 2 – Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others. When market movements occur after the close of the relevant foreign securities markets, foreign securities may be fair valued utilizing an independent pricing service.

Level 3 – Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect Invesco Advisers, Inc.'s assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.

The following is a summary of the tiered valuation input levels, as of January 31, 2026. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| <br>**Investments in Securities** |  |  |  |  |
| Common Stocks & Other Equity Interests | &nbsp;&nbsp;&nbsp;&nbsp; $1141531107 | &nbsp;&nbsp;&nbsp;&nbsp; $49063944 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $1190595051 |
| Money Market Funds | &nbsp;&nbsp;&nbsp;&nbsp; 34563150 | &nbsp;&nbsp;&nbsp;&nbsp; 42730692 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 77293842 |
| **Total Investments** | &nbsp;&nbsp;&nbsp;&nbsp; $1176094257 | &nbsp;&nbsp;&nbsp;&nbsp; $91794636 | &nbsp;&nbsp;&nbsp;&nbsp; $— | &nbsp;&nbsp;&nbsp;&nbsp; $1267888893 |

---

**Invesco Health Care Fund**

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** AIM Investment Funds (Invesco Investment Funds)

- **b. Investment Company Act file number:** 811-05426

- **c. CIK number of Registrant:** 0000826644

- **d. LEI of Registrant:** Y5W0BJB7U2X9V6NIC803

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 11 Greenway Plaza

  - **City:** Houston

  - **State:** TX

  - **Foreign country:** US

  - **Zip / Postal Code:** 77046-1173

  - **Telephone number:** 800-959-4246

**Item A.2. Information about the Series.**

- **a. Name of Series:** Invesco Health Care Fund

- **b. EDGAR series identifier (if any):** S000000235

- **c. LEI of Series:** 549300BBEGFRGDDJRQ35

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-10-31

- **b. Date as of which information is reported:** 2026-01-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1274224951.20

**Total Liabilities:** $43525516.38

**Net Assets:** $1230699434.82

**Cash Not Reported:** $29.68

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000000565 | 7.94%                | -4.33%               | -0.93%               |
| Class ID C000000567 | 7.89%                | -4.42%               | -0.98%               |
| Class ID C000029647 | 7.94%                | -4.33%               | -0.93%               |
| Class ID C000071224 | 7.96%                | -4.31%               | -0.91%               |
| Class ID C000188882 | 8.01%                | -4.33%               | -0.90%               |
| Class ID C000265799 | 7.94%                | -4.36%               | -0.96%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-2156634.86             | $102119193.15                              |
| Month 2  | $14072550.54             | $-72195938.56                              |
| Month 3  | $20426018.90             | $-31644434.18                              |

### Schedule of Portfolio Investments

| Name                                  | Title                                                      | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Ionis Pharmaceuticals, Inc.           | Ionis Pharmaceuticals, Inc.                                | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |    107312 | NS      | $8871483.04   | 0.72%             |  |  |  | No            |                  1 | On Loan: —       |
| Axsome Therapeutics, Inc.             | Axsome Therapeutics, Inc.                                  | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     87700 | NS      | $16158725.00  | 1.31%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd.                  | BeOne Medicines Ltd., ADR                                  | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | CH        |      9251 | NS      | $3148855.38   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                        | Lonza Group AG                                             | CUSIP: N/A<br>LEI: 549300EFW4H2TCZ71055       | Long             | EC               | CORP              | CH        |     14888 | NS      | $10115652.13  | 0.82%             |  |  |  | No            |                  2 | On Loan: No      |
| Arrowhead Pharmaceuticals, Inc.       | Arrowhead Pharmaceuticals, Inc.                            | CUSIP: 04280A100<br>LEI: 549300O3CSB8T7OZ3D66 | Long             | EC               | CORP              | US        |     18515 | NS      | $1283644.95   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                       | AstraZeneca PLC, ADR                                       | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    504742 | NS      | $46824915.34  | 3.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Madrigal Pharmaceuticals, Inc.        | Madrigal Pharmaceuticals, Inc.                             | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |     21162 | NS      | $10354778.22  | 0.84%             |  |  |  | No            |                  1 | On Loan: —       |
| Medpace Holdings, Inc.                | Medpace Holdings, Inc.                                     | CUSIP: 58506Q109<br>LEI: 549300H8TYEUVTW14A54 | Long             | EC               | CORP              | US        |     12424 | NS      | $7236731.52   | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Protagonist Therapeutics, Inc.        | Protagonist Therapeutics, Inc.                             | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    103952 | NS      | $8503273.60   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| IRhythm Holdings, Inc.                | IRhythm Holdings, Inc.                                     | CUSIP: 450056106<br>LEI: 549300FJI72RJGDQS384 | Long             | EC               | CORP              | US        |     47015 | NS      | $7264287.65   | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| argenx SE                             | argenx SE, ADR                                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     52976 | NS      | $44526328.00  | 3.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals, Inc.          | Rhythm Pharmaceuticals, Inc.                               | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |     30683 | NS      | $3145621.16   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Encompass Health Corp.                | Encompass Health Corp.                                     | CUSIP: 29261A100<br>LEI: 549300FVRPM9DRQZRG64 | Long             | EC               | CORP              | US        |    143359 | NS      | $13551726.27  | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| U C B S.A.                            | U C B S.A.                                                 | CUSIP: N/A<br>LEI: 2138008J191VLSGY5A09       | Long             | EC               | CORP              | BE        |     58259 | NS      | $17752999.95  | 1.44%             |  |  |  | No            |                  2 | On Loan: No      |
| Guardant Health, Inc.                 | Guardant Health, Inc.                                      | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |    189772 | NS      | $21641598.88  | 1.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Steris PLC                            | Steris PLC                                                 | CUSIP: G8473T100<br>LEI: 549300F1857N5E6G6T48 | Long             | EC               | CORP              | IE        |     29417 | NS      | $7724904.20   | 0.63%             |  |  |  | No            |                  1 | On Loan: No      |
| TransMedics Group, Inc.               | TransMedics Group, Inc.                                    | CUSIP: 89377M109<br>LEI: 549300060GVOSMWARH50 | Long             | EC               | CORP              | US        |     33601 | NS      | $4501693.98   | 0.37%             |  |  |  | No            |                  1 | On Loan: —       |
| Alnylam Pharmaceuticals, Inc.         | Alnylam Pharmaceuticals, Inc.                              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |     42329 | NS      | $14309741.74  | 1.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Halozyme Therapeutics, Inc.           | Halozyme Therapeutics, Inc.                                | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |    155098 | NS      | $11122077.58  | 0.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Treasury Portfolio            | Invesco Treasury Portfolio, Institutional Class            | CUSIP: 825252406<br>LEI: 5493004B3TM8ZIDDDC39 | Long             | STIV             | RF                | US        |  22695004 | NS      | $22695003.82  | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |
| BridgeBio Pharma, Inc.                | BridgeBio Pharma, Inc.                                     | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |    216227 | NS      | $16707860.29  | 1.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Insulet Corp.                         | Insulet Corp.                                              | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |     52804 | NS      | $13507791.24  | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Phathom Pharmaceuticals, Inc.         | Phathom Pharmaceuticals, Inc.                              | CUSIP: 71722W107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    184910 | NS      | $2527719.70   | 0.21%             |  |  |  | No            |                  1 | On Loan: —       |
| Revolution Medicines, Inc.            | Revolution Medicines, Inc.                                 | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |     27141 | NS      | $2631319.95   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Government & Agency Portfolio | Invesco Government & Agency Portfolio, Institutional Class | CUSIP: 825252885<br>LEI: 5493007T1J7WZ5QI1A47 | Long             | STIV             | RF                | US        |  11868147 | NS      | $11868146.53  | 0.96%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp.               | Boston Scientific Corp.                                    | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    670569 | NS      | $62718318.57  | 5.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Cardinal Health, Inc.                 | Cardinal Health, Inc.                                      | CUSIP: 14149Y108<br>LEI: CCU46N3GJMF4OK4N7U60 | Long             | EC               | CORP              | US        |     44523 | NS      | $9567102.24   | 0.78%             |  |  |  | No            |                  1 | On Loan: No      |
| CVS Health Corp.                      | CVS Health Corp.                                           | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |    119228 | NS      | $8884870.56   | 0.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Private Government Fund       | Invesco Private Government Fund                            | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |  11873857 | NS      | $11873856.76  | 0.96%             |  |  |  | No            |                  2 | On Loan: No      |
| Royalty Pharma PLC                    | Royalty Pharma PLC, Class A                                | CUSIP: G7709Q104<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |    440990 | NS      | $18380463.20  | 1.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Private Prime Fund            | Invesco Private Prime Fund                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |  30856835 | NS      | $30856835.27  | 2.51%             |  |  |  | No            |                  2 | On Loan: No      |
| Gilead Sciences, Inc.                 | Gilead Sciences, Inc.                                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    337004 | NS      | $47837717.80  | 3.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                     | Johnson & Johnson                                          | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    184830 | NS      | $42002617.50  | 3.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Cogent Biosciences, Inc.              | Cogent Biosciences, Inc.                                   | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     74261 | NS      | $2666712.51   | 0.22%             |  |  |  | No            |                  1 | On Loan: —       |
| Tarsus Pharmaceuticals, Inc.          | Tarsus Pharmaceuticals, Inc.                               | CUSIP: 87650L103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     77845 | NS      | $5024116.30   | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly and Co.                     | Eli Lilly and Co.                                          | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    113267 | NS      | $117474869.05 | 9.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Quest Diagnostics Inc.                | Quest Diagnostics Inc.                                     | CUSIP: 74834L100<br>LEI: 8MCWUBXQ0WE04KMXBX50 | Long             | EC               | CORP              | US        |     20984 | NS      | $3924637.52   | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc.           | Vertex Pharmaceuticals Inc.                                | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     32280 | NS      | $15168372.00  | 1.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Alignment Healthcare, Inc.            | Alignment Healthcare, Inc.                                 | CUSIP: 01625V104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    323803 | NS      | $7295281.59   | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp.            | Edwards Lifesciences Corp.                                 | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    140197 | NS      | $11406427.92  | 0.93%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc.               | UnitedHealth Group Inc.                                    | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |     59237 | NS      | $16996872.41  | 1.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp.                         | Stryker Corp.                                              | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |     34934 | NS      | $12910209.04  | 1.05%             |  |  |  | No            |                  1 | On Loan: No      |
| United Therapeutics Corp.             | United Therapeutics Corp.                                  | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |     26773 | NS      | $12569655.77  | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc.         | Thermo Fisher Scientific Inc.                              | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     49606 | NS      | $28702527.66  | 2.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical, Inc.              | Intuitive Surgical, Inc.                                   | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |     45537 | NS      | $22960666.14  | 1.87%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent, Inc.                        | Nuvalent, Inc., Class A                                    | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     33246 | NS      | $3420680.94   | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| LeMaitre Vascular, Inc.               | LeMaitre Vascular, Inc.                                    | CUSIP: 525558201<br>LEI: 549300FZUBUB7MHY8R17 | Long             | EC               | CORP              | US        |     44039 | NS      | $3741993.83   | 0.30%             |  |  |  | No            |                  1 | On Loan: —       |
| Exelixis, Inc.                        | Exelixis, Inc.                                             | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |     96756 | NS      | $4001828.16   | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| RadNet, Inc.                          | RadNet, Inc.                                               | CUSIP: 750491102<br>LEI: 529900RECG94V2IZJ970 | Long             | EC               | CORP              | US        |     62732 | NS      | $4397513.20   | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora, Inc.                         | Cencora, Inc.                                              | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |    162214 | NS      | $58270513.08  | 4.73%             |  |  |  | No            |                  1 | On Loan: No      |
| GeneDx Holdings Corp.                 | GeneDx Holdings Corp.                                      | CUSIP: 81663L200<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     50738 | NS      | $4884039.88   | 0.40%             |  |  |  | No            |                  1 | On Loan: —       |
| HCA Healthcare, Inc.                  | HCA Healthcare, Inc.                                       | CUSIP: 40412C101<br>LEI: 529900PH4ZGUH2MNEU89 | Long             | EC               | CORP              | US        |     49432 | NS      | $24136162.64  | 1.96%             |  |  |  | No            |                  1 | On Loan: No      |
| Mettler-Toledo International Inc.     | Mettler-Toledo International Inc.                          | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |      9732 | NS      | $13364371.68  | 1.09%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX Laboratories, Inc.              | IDEXX Laboratories, Inc.                                   | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |     29150 | NS      | $19543909.00  | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Sandoz Group AG                       | Sandoz Group AG                                            | CUSIP: H7140B103<br>LEI: 5493000JWK6XWFEUD320 | Long             | EC               | CORP              | CH        |    150537 | NS      | $11926417.83  | 0.97%             |  |  |  | No            |                  2 | On Loan: No      |
| BrightSpring Health Services, Inc.    | BrightSpring Health Services, Inc.                         | CUSIP: 10950A106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    482157 | NS      | $18934305.39  | 1.54%             |  |  |  | No            |                  1 | On Loan: —       |
| Galderma Group AG                     | Galderma Group AG, Class A                                 | CUSIP: H3301B107<br>LEI: 89450001OK6O8ELQ4584 | Long             | EC               | CORP              | CH        |     49726 | NS      | $9268873.92   | 0.75%             |  |  |  | No            |                  2 | On Loan: No      |
| Labcorp Holdings Inc.                 | Labcorp Holdings Inc.                                      | CUSIP: 504922105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     22180 | NS      | $6022313.60   | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Rapport Therapeutics, Inc.            | Rapport Therapeutics, Inc.                                 | CUSIP: 75383L102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    109966 | NS      | $2926195.26   | 0.24%             |  |  |  | No            |                  1 | On Loan: —       |
| Globus Medical, Inc.                  | Globus Medical, Inc., Class A                              | CUSIP: 379577208<br>LEI: 5299003M2P4CIK0RF205 | Long             | EC               | CORP              | US        |     65282 | NS      | $5919771.76   | 0.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Agilent Technologies, Inc.            | Agilent Technologies, Inc.                                 | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |     87517 | NS      | $11714150.45  | 0.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Caris Life Sciences, Inc.             | Caris Life Sciences, Inc.                                  | CUSIP: 142152107<br>LEI: 549300LX5LO78M5VPY43 | Long             | EC               | CORP              | US        |    110484 | NS      | $2558809.44   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Tenet Healthcare Corp.                | Tenet Healthcare Corp.                                     | CUSIP: 88033G407<br>LEI: 0W9AIBT6U6ADJ2I8HK17 | Long             | EC               | CORP              | US        |     80222 | NS      | $15184420.16  | 1.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Heartflow, Inc.                       | Heartflow, Inc.                                            | CUSIP: 42238D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    121178 | NS      | $3619586.86   | 0.29%             |  |  |  | No            |                  1 | On Loan: —       |
| BillionToOne, Inc.                    | BillionToOne, Inc.                                         | CUSIP: 090168105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     14768 | NS      | $1218507.68   | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| AbbVie Inc.                           | AbbVie Inc.                                                | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    277017 | NS      | $61777561.17  | 5.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc.                           | Insmed Inc.                                                | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |    120502 | NS      | $18903148.74  | 1.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Icon PLC                              | Icon PLC                                                   | CUSIP: G4705A100<br>LEI: 6354008SRQGEMC4XFI67 | Long             | EC               | CORP              | IE        |     25368 | NS      | $4572582.00   | 0.37%             |  |  |  | No            |                  1 | On Loan: No      |
| McKesson Corp.                        | McKesson Corp.                                             | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |     47553 | NS      | $39526529.13  | 3.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics, Inc.                    | Cytokinetics, Inc.                                         | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |     48114 | NS      | $3040323.66   | 0.25%             |  |  |  | No            |                  1 | On Loan: —       |
| BioLife Solutions, Inc.               | BioLife Solutions, Inc.                                    | CUSIP: 09062W204<br>LEI: 549300G2IVCMC2TJDW72 | Long             | EC               | CORP              | US        |    151657 | NS      | $3306122.60   | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals, Inc.       | Regeneron Pharmaceuticals, Inc.                            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     18122 | NS      | $13436556.90  | 1.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Ligand Pharmaceuticals Inc.           | Ligand Pharmaceuticals Inc.                                | CUSIP: 53220K504<br>LEI: 5493008K7TB0IKP37H79 | Long             | EC               | CORP              | US        |     40048 | NS      | $7693220.80   | 0.63%             |  |  |  | No            |                  1 | On Loan: —       |
| HealthEquity, Inc.                    | HealthEquity, Inc.                                         | CUSIP: 42226A107<br>LEI: 529900LRJU1RAFQHM467 | Long             | EC               | CORP              | US        |     43670 | NS      | $3741208.90   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| ADMA Biologics, Inc.                  | ADMA Biologics, Inc.                                       | CUSIP: 000899104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    136705 | NS      | $2364996.50   | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                   | Ascendis Pharma A/S, ADR                                   | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |     94558 | NS      | $21379563.80  | 1.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp.                        | Repligen Corp.                                             | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |     50803 | NS      | $7588444.11   | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera, Inc.                          | Natera, Inc.                                               | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |     86013 | NS      | $19881044.82  | 1.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Welltower Inc.                        | Welltower Inc.                                             | CUSIP: 95040Q104<br>LEI: 254900F33BIAR82QTA19 | Long             | EC               | CORP              | US        |    120441 | NS      | $22686266.76  | 1.84%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-03-02

**Name of Applicant:** AIM Investment Funds (Invesco Investment Funds)

**Signature:** Adrien Deberghes

**Name of Signer:** Adrien Deberghes

**Title:** Principal Financial Officer and Treasurer